These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 23788743)

  • 1. Context sensitive decrement times of remimazolam.
    Schnider T; Minto C
    Anesth Analg; 2013 Jul; 117(1):285. PubMed ID: 23788743
    [No Abstract]   [Full Text] [Related]  

  • 2. Remimazolam: new beginnings or just a me-too?
    Sneyd JR
    Anesth Analg; 2012 Aug; 115(2):217-9. PubMed ID: 22826518
    [No Abstract]   [Full Text] [Related]  

  • 3. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation.
    Wiltshire HR; Kilpatrick GJ; Tilbrook GS; Borkett KM
    Anesth Analg; 2012 Aug; 115(2):284-96. PubMed ID: 22253270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recirculatory pharmacokinetic modeling: what goes around, comes around.
    Krejcie TC; Avram MJ
    Anesth Analg; 2012 Aug; 115(2):223-6. PubMed ID: 22826520
    [No Abstract]   [Full Text] [Related]  

  • 5. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics.
    Antonik LJ; Goldwater DR; Kilpatrick GJ; Tilbrook GS; Borkett KM
    Anesth Analg; 2012 Aug; 115(2):274-83. PubMed ID: 22190555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New horizons in sedative hypnotic drug development: fast, clean, and soft.
    Johnson KB
    Anesth Analg; 2012 Aug; 115(2):220-2. PubMed ID: 22826519
    [No Abstract]   [Full Text] [Related]  

  • 7. Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.
    Rogers WK; McDowell TS
    IDrugs; 2010 Dec; 13(12):929-37. PubMed ID: 21154153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remimazolam: Pharmacologic Considerations and Clinical Role in Anesthesiology.
    Wesolowski AM; Zaccagnino MP; Malapero RJ; Kaye AD; Urman RD
    Pharmacotherapy; 2016 Sep; 36(9):1021-7. PubMed ID: 27496519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time-to-Event Modeling for Remimazolam for the Indication of Induction and Maintenance of General Anesthesia.
    Lohmer LL; Schippers F; Petersen KU; Stoehr T; Schmith VD
    J Clin Pharmacol; 2020 Apr; 60(4):505-514. PubMed ID: 31989598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remimazolam Has Low Oral Bioavailability and No Potential for Misuse in Drug-Facilitated Sexual Assaults, with or Without Alcohol: Results from Two Randomised Clinical Trials.
    Pesic M; Stöhr T; Ossig J; Borkett K; Donsbach M; Dao VA; Webster L; Schippers F
    Drugs R D; 2020 Sep; 20(3):267-277. PubMed ID: 32757149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of time-dependent inactivation on the estimation of enzyme kinetic parameters for midazolam.
    Giragossian C; LaPerle J; Kosa RE; Gillian S
    Drug Metab Lett; 2009 Jan; 3(1):45-53. PubMed ID: 19356116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase IIa, randomized, double-blind study of remimazolam (CNS 7056) versus midazolam for sedation in upper gastrointestinal endoscopy.
    Borkett KM; Riff DS; Schwartz HI; Winkle PJ; Pambianco DJ; Lees JP; Wilhelm-Ogunbiyi K
    Anesth Analg; 2015 Apr; 120(4):771-80. PubMed ID: 25502841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase IIb study comparing the safety and efficacy of remimazolam and midazolam in patients undergoing colonoscopy.
    Pambianco DJ; Borkett KM; Riff DS; Winkle PJ; Schwartz HI; Melson TI; Wilhelm-Ogunbiyi K
    Gastrointest Endosc; 2016 May; 83(5):984-92. PubMed ID: 26363333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simulation of residual sedation effect of remimazolam: pharmacokinetic-pharmacodynamic simulation can be an additional standard anesthesia monitoring method.
    Obara S
    J Anesth; 2022 Apr; 36(2):167-170. PubMed ID: 34160699
    [No Abstract]   [Full Text] [Related]  

  • 15. What May Be the First Phase 4 Experience with BYFAVO (Remimazolam).
    Henson KS; Thompson KJ
    AANA J; 2021 Apr; 89(2):101-102. PubMed ID: 33832568
    [No Abstract]   [Full Text] [Related]  

  • 16. A maturation model for midazolam clearance.
    Anderson BJ; Larsson P
    Paediatr Anaesth; 2011 Mar; 21(3):302-8. PubMed ID: 20704661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re-sleeping after reversal of remimazolam by flumazenil.
    Yamamoto T; Kurabe M; Kamiya Y
    J Anesth; 2021 Apr; 35(2):322. PubMed ID: 33687549
    [No Abstract]   [Full Text] [Related]  

  • 18. Remimazolam anaphylaxis during anesthesia induction.
    Tsurumi K; Takahashi S; Hiramoto Y; Nagumo K; Takazawa T; Kamiyama Y
    J Anesth; 2021 Aug; 35(4):571-575. PubMed ID: 34050439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remimazolam: a new reminder to keep our guard up.
    Abad-Gurumeta A; Gómez-Ríos MA
    Minerva Anestesiol; 2023 Jun; 89(6):495-497. PubMed ID: 37158630
    [No Abstract]   [Full Text] [Related]  

  • 20. Electroencephalogram inability to detect intraoperative awakening in a patient with remimazolam tolerance.
    Kawashima S; Kinoshita H; Kawashima W; Nakajima Y
    Minerva Anestesiol; 2023 May; 89(5):482-483. PubMed ID: 36383081
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.